Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 12, 2025
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV
Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025
Read more at globenewswire.com
